Vogenx, Inc. (Nasdaq: VOGX) announced the appointment of Ken Toombs to its Board of Directors in a filing dated September 21, 2026. Mr. Toombs will serve as an independent director and will chair the Audit Committee. His term is set to run until the 2028 annual meeting of stockholders or until his successor is duly elected and qualified.
The appointment was made effective September 21, 2026, and coincides with the Board also appointing Peter Pieraccini to serve as Chair of the Compensation Committee. Mr. Toombs brings over three decades of experience in the global professional services industry. He most recently served as the Chief Executive Officer of PA Consulting, a London-headquartered innovation and transformation consultancy, a role he assumed in October 2020. Prior to that, he held leadership positions at Infosys Consulting, Capgemini Consulting, and PricewaterhouseCoopers.
According to the company’s press release, Mr. Toombs holds a B.S. in accounting from the University of Southern California and an M.B.A. from the Kellogg School of Management at Northwestern University. He is based in the Research Triangle region of North Carolina. The filing states that Mr. Toombs entered into the Company’s standard form of Director and Officer Indemnification Agreement and will receive compensation for his service as a non-employee director in accordance with the Company’s Non-Employee Director Compensation Policy.
In a statement regarding the appointment, James Green, Chief Executive Officer and Chairman of the Board of Vogenx, noted that Mr. Toombs has a deep familiarity with healthcare and life sciences and that his judgment on building and scaling an organization will be valuable as the company continues to grow.
The press release accompanying the filing provides context on Vogenx’s operations. The company is a clinical-stage biopharmaceutical company based in Raleigh, North Carolina, focused on the discovery and development of novel therapeutics for serious metabolic and gastrointestinal diseases. Its lead product candidate is mizagliflozin, an investigational, first-in-class small molecule inhibitor of the sodium-dependent glucose transporter 1 (SGLT1). The company is developing this molecule for the treatment of post-bariatric hypoglycemia, gastroparesis, and GIP-dependent Cushing’s Syndrome. The press release notes that mizagliflozin has been administered to more than 500 subjects in 10 clinical studies and has shown statistically significant reductions in postprandial glucose absorption and insulin secretion.
